| Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor A Evers, T Klabunde Journal of medicinal chemistry 48 (4), 1088-1097, 2005 | 326 | 2005 |
| Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein-and ligand-based virtual screening protocols A Evers, G Hessler, H Matter, T Klabunde Journal of medicinal chemistry 48 (17), 5448-5465, 2005 | 237 | 2005 |
| Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model A Evers, G Klebe Journal of medicinal chemistry 47 (22), 5381-5392, 2004 | 215 | 2004 |
| Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity M Lorenz, A Evers, M Wagner Bioorganic & medicinal chemistry letters 23 (14), 4011-4018, 2013 | 167 | 2013 |
| Comparison of structure‐and ligand‐based virtual screening protocols considering hit list complementarity and enrichment factors DM Krüger, A Evers ChemMedChem: Chemistry Enabling Drug Discovery 5 (1), 148-158, 2010 | 142 | 2010 |
| Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials A Evers, H Gohlke, G Klebe Journal of molecular biology 334 (2), 327-345, 2003 | 142 | 2003 |
| Ligand‐supported homology modeling of G‐protein‐coupled receptor sites: models sufficient for successful virtual screening A Evers, G Klebe Angewandte Chemie International Edition 43 (2), 248-251, 2004 | 133 | 2004 |
| GPCR antitarget modeling: pharmacophore models for biogenic amine binding GPCRs to avoid GPCR‐mediated side effects T Klabunde, A Evers ChemBioChem 6 (5), 876-889, 2005 | 117 | 2005 |
| Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist M Bossart, M Wagner, R Elvert, A Evers, T Hübschle, T Kloeckener, ... Cell metabolism 34 (1), 59-74. e10, 2022 | 112 | 2022 |
| Design of novel exendin-based dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists A Evers, T Haack, M Lorenz, M Bossart, R Elvert, B Henkel, S Stengelin, ... Journal of medicinal chemistry 60 (10), 4293-4303, 2017 | 102 | 2017 |
| Sequence-derived three-dimensional pharmacophore models for G-protein-coupled receptors and their application in virtual screening T Klabunde, C Giegerich, A Evers Journal of medicinal chemistry 52 (9), 2923-2932, 2009 | 71 | 2009 |
| Multiple-ligand-based virtual screening: methods and applications of the MTree approach G Hessler, M Zimmermann, H Matter, A Evers, T Naumann, T Lengauer, ... Journal of medicinal chemistry 48 (21), 6575-6584, 2005 | 55 | 2005 |
| Dual glucagon-like peptide 1 (GLP-1)/glucagon receptor agonists specifically optimized for multidose formulations A Evers, M Bossart, S Pfeiffer-Marek, R Elvert, H Schreuder, M Kurz, ... Journal of medicinal chemistry 61 (13), 5580-5593, 2018 | 51 | 2018 |
| Crystal structure of 2-methylisocitrate lyase (PrpB) from Escherichia coli and modelling of its ligand bound active centre C Grimm, A Evers, M Brock, C Maerker, G Klebe, W Buckel, K Reuter Journal of molecular biology 328 (3), 609-621, 2003 | 46 | 2003 |
| Novel small molecule inhibitors of activated thrombin activatable fibrinolysis inhibitor (TAFIa) from natural product anabaenopeptin N Halland, M Brönstrup, J Czech, W Czechtizky, A Evers, M Follmann, ... Journal of Medicinal Chemistry 58 (11), 4839-4844, 2015 | 40 | 2015 |
| The Potential of P1 Site Alterations in Peptidomimetic Protease Inhibitors as Suggested by Virtual Screening and Explored by the Use of C C‐Coupling Reagents S Weik, T Luksch, A Evers, J Böttcher, CA Sotriffer, A Hasilik, HG Löffler, ... ChemMedChem: Chemistry Enabling Drug Discovery 1 (4), 445-457, 2006 | 38 | 2006 |
| Selective non-lipid modulator of LPA5 activity in human platelets DH Kozian, A Evers, P Florian, P Wonerow, S Joho, M Nazare Bioorganic & medicinal chemistry letters 22 (16), 5239-5243, 2012 | 37 | 2012 |
| Running on mixed fuel‐dual agonistic approach of GLP‐1 and GCG receptors leads to beneficial impact on body weight and blood glucose control: a comparative study between mice … R Elvert, AW Herling, M Bossart, T Weiss, B Zhang, P Wenski, ... Diabetes, Obesity and Metabolism 20 (8), 1836-1851, 2018 | 35 | 2018 |
| Identification of High-Affinity P2Y12 Antagonists Based on a Phenylpyrazole Glutamic Acid Piperazine Backbone G Zech, G Hessler, A Evers, T Weiss, P Florian, M Just, J Czech, ... Journal of Medicinal Chemistry 55 (20), 8615-8629, 2012 | 34 | 2012 |
| Incretin combination therapy for the treatment of non‐alcoholic steatohepatitis A Kannt, AN Madsen, C Kammermeier, R Elvert, T Klöckener, M Bossart, ... Diabetes, Obesity and Metabolism 22 (8), 1328-1338, 2020 | 33 | 2020 |
